These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 35982541)

  • 21. Antiretroviral Therapy Anchor-based Trends in Body Mass Index Following Treatment Initiation Among Military Personnel with HIV.
    Kline MDA; Daniels C; Xu X; Sunil T; Ganesan A; Agan BK; Colombo RE; Kronmann KC; Blaylock JM; Okulicz JF; Markelz AE
    Mil Med; 2021 Feb; 186(3-4):279-285. PubMed ID: 33128552
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy.
    Bourgi K; Rebeiro PF; Turner M; Castilho JL; Hulgan T; Raffanti SP; Koethe JR; Sterling TR
    Clin Infect Dis; 2020 Mar; 70(7):1267-1274. PubMed ID: 31100116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens.
    Raffi F; Esser S; Nunnari G; Pérez-Valero I; Waters L
    HIV Med; 2016 Oct; 17 Suppl 5():3-16. PubMed ID: 27714978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiretroviral therapy in older people with HIV.
    Richterman A; Sax PE
    Curr Opin HIV AIDS; 2020 Mar; 15(2):118-125. PubMed ID: 31990705
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV-associated neurocognitive disorders at Moi teaching and referral hospital, Eldoret, Kenya.
    Mohamed AA; Oduor C; Kinyanjui D
    BMC Neurol; 2020 Jul; 20(1):280. PubMed ID: 32664858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brief Report: Intracellular Cystatin B Levels Are Altered in HIV-Infected Participants With Respect to Neurocognitive Status and Antiretroviral Therapy.
    Opsteen S; Moylan D; Taiwo BO; Robertson KR; Overton ET; Cutter GR; Sabbaj S; Heath SL; Shacka JJ
    J Acquir Immune Defic Syndr; 2022 Dec; 91(5):485-489. PubMed ID: 36083516
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Depression and HIV associated neurocognitive disorders among HIV infected adults in rural southwestern Uganda: a cross-sectional quantitative study.
    Namagga JK; Rukundo GZ; Niyonzima V; Voss J
    BMC Psychiatry; 2021 Jul; 21(1):350. PubMed ID: 34253176
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study.
    Serrano-Villar S; Martínez-Sanz J; Ron R; Talavera-Rodríguez A; Fernández-Felix BM; Herrera S; Muriel A; Fanjul F; Portilla J; Muñoz J; Amador C; de Zárraga MA; Vivancos MJ; Moreno S;
    Lancet HIV; 2020 Aug; 7(8):e565-e573. PubMed ID: 32763219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Coagulation imbalance and neurocognitive functioning in older HIV-positive adults on suppressive antiretroviral therapy.
    Montoya JL; Iudicello J; Oppenheim HA; Fazeli PL; Potter M; Ma Q; Mills PJ; Ellis RJ; Grant I; Letendre SL; Moore DJ;
    AIDS; 2017 Mar; 31(6):787-795. PubMed ID: 28099190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The age-related trajectory of visual attention neural function is altered in adults living with HIV: A cross-sectional MEG study.
    Arif Y; Wiesman AI; O'Neill J; Embury C; May PE; Lew BJ; Schantell MD; Fox HS; Swindells S; Wilson TW
    EBioMedicine; 2020 Nov; 61():103065. PubMed ID: 33099087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rates of non-confounded HIV-associated neurocognitive disorders in men initiating combination antiretroviral therapy during primary infection.
    Evering TH; Applebaum A; La Mar M; Garmon D; Dorfman D; Markowitz M
    AIDS; 2016 Jan; 30(2):203-10. PubMed ID: 26684817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients.
    Ciccarelli N; Fabbiani M; Di Giambenedetto S; Fanti I; Baldonero E; Bracciale L; Tamburrini E; Cauda R; De Luca A; Silveri MC
    Neurology; 2011 Apr; 76(16):1403-9. PubMed ID: 21502598
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vascular injury markers associated with cognitive impairment in people with HIV on suppressive antiretroviral therapy.
    Guha D; Misra V; Yin J; Horiguchi M; Uno H; Gabuzda D
    AIDS; 2023 Nov; 37(14):2137-2147. PubMed ID: 37503603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral-naïve persons starting treatment.
    Mocroft A; Neesgard B; Zangerle R; Rieger A; Castagna A; Spagnuolo V; Antinori A; Lampe FC; Youle M; Vehreschild JJ; Mussini C; Borghi V; Begovac J; Duvivier C; Gunthard HF; Rauch A; Tiraboschi J; Chkhartishvili N; Bolokadze N; Wit F; Wasmuth JC; De Wit S; Necsoi C; Pradier C; Svedhem V; Stephan C; Petoumenos K; Garges H; Rogatto F; Peters L; Ryom L;
    HIV Med; 2020 Oct; 21(9):599-606. PubMed ID: 32588958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrase inhibitor-based regimens result in more rapid virologic suppression rates among treatment-naïve human immunodeficiency virus-infected patients compared to non-nucleoside and protease inhibitor-based regimens in a real-world clinical setting: A retrospective cohort study.
    Jacobson K; Ogbuagu O
    Medicine (Baltimore); 2018 Oct; 97(43):e13016. PubMed ID: 30412140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Screening for Neurocognitive Impairment in HIV-Infected Individuals at First Contact after HIV Diagnosis: The Experience of a Large Clinical Center in Northern Italy.
    Focà E; Magro P; Motta D; Compostella S; Casari S; Bonito A; Brianese N; Ferraresi A; Rodari P; Pezzoli MC; Quiros-Roldan E; Castelli F
    Int J Mol Sci; 2016 Mar; 17(4):434. PubMed ID: 27023519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Virologic outcomes among adults with HIV using integrase inhibitor-based antiretroviral therapy.
    Lu H; Cole SR; Westreich D; Hudgens MG; Adimora AA; Althoff KN; Silverberg MJ; Buchacz K; Li J; Edwards JK; Rebeiro PF; Lima VD; Marconi VC; Sterling TR; Horberg MA; Gill MJ; Kitahata MM; Eron JJ; Moore RD;
    AIDS; 2022 Feb; 36(2):277-286. PubMed ID: 34934020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of integrase strand transfer inhibitor (INSTIs) resistance mutations in Henan Province, China (2018-2020).
    Yang Z; Yang X; Deng X; Wei S; Liu J; Ma J; Zhao Q; Huo Y
    Infection; 2021 Dec; 49(6):1195-1202. PubMed ID: 34279816
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of antiretroviral third agent virologic durability after initiation of first antiretroviral regimen.
    Varriano B; Sandler I; Loutfy M; Steinberg S; Smith G; Kovacs C; Brunetta J; Fletcher D; Knox D; Merkley B; Chang B; Tilley D; Acsai M; Crouzat F
    Int J STD AIDS; 2019 Jun; 30(7):680-688. PubMed ID: 31042101
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV associated neurocognitive disorders (HAND) in Malawian adults and effect on adherence to combination anti-retroviral therapy: a cross sectional study.
    Kelly CM; van Oosterhout JJ; Ngwalo C; Stewart RC; Benjamin L; Robertson KR; Khoo S; Allain TJ; Solomon T
    PLoS One; 2014; 9(6):e98962. PubMed ID: 24915530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.